Fig. 3From: Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysisMaximum purchase price for a course of treatment to remain cost-effective assuming a cost-effectiveness threshold of £20,000 QALY. a Probability of cost-effectiveness for each of the non-dominated programmes over a range of purchasing prices. b Sensitivity analysis on the duration of protection for the monoclonal antibodies and its effect on the maximum purchasing price per courseBack to article page